Nanding, Zuilybeth S.
HRN: 18-60-81 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/17/2022
CEFUROXIME 750MG (VIAL)
07/17/2022
07/24/2022
IV
500mg
Q8h
PCAP C UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary TractPneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes